A Study of CST-2032 in Subjects With Cognitive Impairment
Status:
Withdrawn
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of CST-2032 when administered with pre-administered
CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in
patients with cognitive impairment.